Assessment of safety and feasibility of Immunoadsorption Therapy for Dilated Cardiomyopathy Patients with LVAD

Assessment of safety and feasibility of Immunoadsorption Therapy for Dilated Cardiomyopathy Patients with LVAD - Assessment of safety and feasibility of Immunoadsorption Therapy for Dilated Cardiomyopathy Patients with LVAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012944

Enrollment

Registered

2014-01-24

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated Cardiomyopathy

Interventions

5 sessions of immunoadsorption therapy using Immusorba TR will be performed in 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: idiopathic dilated cardiomyopathy NYHA functional Class iv and patient sustaining life by LVAD patient with LVAD

Exclusion criteria

Exclusion criteria: Secondary DCM Received Cardiac resynchronization therapy(CRT or CRT-D) in the past 6 months Received Heart transplantation

Design outcomes

Primary

Measure	Time frame
number of adverse event	—

Countries

Japan

Contacts

Public ContactDaisuke,Yoshioka

Osaka University Graduate School of Medicine Division of Cardiovascular Surgery

yoshioka@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026